About
Douglas Mulhall is a co-founder of Elastrin Therapeutics, a longevity/cardiovascular biotech focused on reversing vascular calcification. He also has a long career in circular-economy and healthy-materials work, including EPEA and research affiliations at Technical University of Munich and Delft University of Technology. His public profile is stronger as a scientific/product and ecosystem figure than as a capital allocator.
Areas of interest
longevitybiotechcardiovascular healthvascular calcificationbiomaterialshealthy productscircular economysustainable buildingsstandards development